Lyra Therapeutics (NASDAQ:LYRA) & Regenicin (OTCMKTS:RGIN) Critical Review

Regenicin (OTCMKTS:RGIN) and Lyra Therapeutics (NASDAQ:LYRA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, profitability, risk, institutional ownership, dividends, valuation and earnings.

Insider & Institutional Ownership

0.0% of Regenicin shares are owned by institutional investors. Comparatively, 95.6% of Lyra Therapeutics shares are owned by institutional investors. 4.7% of Lyra Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Risk & Volatility

Regenicin has a beta of -18.91, indicating that its share price is 1,991% less volatile than the S&P 500. Comparatively, Lyra Therapeutics has a beta of -0.13, indicating that its share price is 113% less volatile than the S&P 500.

Earnings and Valuation

This table compares Regenicin and Lyra Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regenicin	N/A	N/A	-$640,000.00	N/A	N/A
Lyra Therapeutics	$1.47 million	9.52	-$62.68 million	($1.49)	-0.14

Regenicin has higher earnings, but lower revenue than Lyra Therapeutics.

Profitability

This table compares Regenicin and Lyra Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Regenicin	N/A	N/A	N/A
Lyra Therapeutics	-6,635.76%	-125.07%	-59.74%

Analyst Recommendations

This is a breakdown of current ratings and price targets for Regenicin and Lyra Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regenicin	0	0	0	0	0.00
Lyra Therapeutics	1	4	1	0	2.00

Lyra Therapeutics has a consensus target price of $4.50, suggesting a potential upside of 2,002.80%. Given Lyra Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Lyra Therapeutics is more favorable than Regenicin.

Summary

Lyra Therapeutics beats Regenicin on 7 of the 11 factors compared between the two stocks.

About Regenicin

Regenicin, Inc. focuses on developing and commercializing a technology of tissue-engineered skin substitutes. Its product portfolio includes NovaDerm, a multi-layered tissue-engineered living skin and cultured skin substitute product for the treatment of burns; and TempaDerm to treat smaller wound areas on patients, such as ulcers. The company products are used to restore the qualities of healthy human skin for use in the treatment of burns, chronic wounds, and various plastic surgery procedures. The company was formerly known as Windstar, Inc. and changed its name to Regenicin, Inc. in July 2010. Regenicin, Inc. was incorporated in 2007 and is headquartered in Little Falls, New Jersey.

About Lyra Therapeutics

Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase III clinical trial; and LYR-220 for CRS patients with and without nasal polyps. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.